Press Releases
AVROBIO, Inc. Appoints Annalisa Jenkins to its Board of Directors
Industry Leader Brings Gene Therapy and Pharmaceutical Expertise as Former CEO of Dimension Therapeutics, Head of Global R&D for Merck Serono and Head of Global Medical Affairs
AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases
Company to initiate Phase 2 trial with lead gene therapy, AVR-RD-01, based on promising initial clinical data in Fabry disease Strong investor syndicate supports multi-product portfolio with
AVROBIO, Inc. Appoints Ian Clark to its Board of Directors
Appointment of Industry Veteran Ian Clark Brings Wealth of Leadership, Strategic and Operational Experience Cambridge, MA, November 9, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing
AVROBIO Reports Six-Month Data Showing First Patient Treated for Fabry Disease Achieved Normal Plasma Enzyme Activity with AVR-RD-01 Gene Therapy
First patient with Fabry disease who received a single dose of lentiviral gene therapy achieved normal plasma α-galactosidase A enzyme activity within 45 days and has maintained
AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis
Cystinosis Program Becomes Company’s Fourth Gene Therapy for Lysosomal Storage Disorders Cambridge, MA, October 4, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene
AVROBIO, Inc. Appoints Katina Dorton as Chief Financial Officer
Cambridge, MA, September 26, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, announces today the appointment of Katina Dorton